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ABSTRACT
The fluorinated pyrimidine 5-fluorouracil (5-FU) is an
anticancer agent used in most adjuvant and palliative
treatment regimens for colorectal cancer. Neurotox-
icities are considered extremely rare side effects of
5-FU. Here, we report a case of 5-FU–induced en-
cephalopathy, manifesting as seizures and delirium,
in an era of oxaliplatin-containing chemotherapy. If
ammonia levels are elevated, lactulose may be con-
sidered in the initial management of neuropsychiatric
complications from 5-FU.
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1. CASE DESCRIPTION
A 53-year-old Korean man who had undergone cura-
tive surgical resection for stage III (T3N2M0) colon
cancer was evaluated in clinic by his medical oncolo-
gist before the start of adjuvant chemotherapy. He ap-
peared clinically well on assessment and proceeded
to receive his first cycle of modified FOLFOX-6
chemotherapy. This regimen consisted of oxaliplatin
85 mg/m2, folinic acid 400 mg/m2, and 5-fluorouracil
(5-FU) 400 mg/m2 bolus on day 1, followed by 5-FU
2400 mg/m2 by continuous infusion over the next 46
hours. Dexamethasone 12 mg and ondansetron 8 mg
were given as pre-medication before chemotherapy.
The patient experienced no acute side effects or
complications in the chemotherapy unit. He was dis-
charged home with an ambulatory 5-FU pump and was
scheduled to return to the clinic at completion of his 5-
FU infusion.
Twenty-four hours later, the patient presented to
the emergency department with new symptoms of er-
ratic behaviour and confusion. Collateral history from
the accompanying family members revealed that he
had suffered a brief generalized tonic–clonic seizure
earlier in the day, but no apparent history of head inju-
ries, infectious symptoms, or recent alcohol intake was
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present. The patient’s other medical problems included
well-controlled hypertension, hyperlipidemia, poly-
cystic kidney disease, chronic renal insufficiency (base-
line creatinine: 172 mmol/L), and stable chronic
hepatitis B carrier status without laboratory or radio-
logic evidence of cirrhosis. No history of epilepsy was
present. The patient’s only oral medications were
amlodipine, quinapril, hydrochlorothiazide, and
atorvastatin. He was an ex-smoker, and he denied al-
cohol abuse and illicit drugs.
On examination in the emergency department, the
patient was neither alert nor oriented. He was unable
to follow commands, and his verbal responses were
incomprehensible. He was agitated, and his limbs
were tremulous at rest. Temperature was 35.9°C;
heart rate, 82/min; respirations, 18/min; blood pres-
sure, 130/84 mmHg; and O2 saturation on room air,
99%. The patient’s eyes appeared deviated to his left
side, but pupils were equal and reactive. Spontaneous
twitching of the extremities, on the left side more than
on the right, was noted and attributed to possible com-
plex partial seizures. No other focal neurologic defi-
cits or evidence of trauma were present. The Brudzinski
and Kernig signs were negative. Examinations of chest,
heart, and abdomen were otherwise unremarkable. The
patient was noted to be incontinent of urine during the
assessment. He was treated with intravenous diazepam
and phenytoin (given in a loading dose of 1000 mg) for
his agitation and presumed seizure activity respectively.
At this point, his 5-FU infusion pump was still attached
and functioning.
Laboratory investigations showed leucocytosis
(white blood cell count: 19.5 ×109/L) with left shift, but
an otherwise normal complete blood cell count. Liver
enzyme tests were within normal limits. Serum cre-
atinine and blood urea nitrogen were elevated (239
mmol/L and 8.6 mmol/L respectively). Metabolic aci-
dosis with an anion gap of 29 mmol/L was present.
Imaging of the head and brain by computed tomogra-
phy and magnetic resonance imaging scan respectively
did not demonstrate evidence of infarction, hemorrhage,
mass, or other abnormalities. Cerebrospinal fluid analy-
sis was benign, and subsequent cultures of cerebrospi-
nal fluid, blood, and urine were all negative. Of note,CHEUNG et al.
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serum ammonia, at 316 mmol/L, and serum lactate, at
8.3 mmol/L, were elevated. The remainder of the toxi-
cology screen was completely unremarkable. Vitamin
B12 level and thyroid function tests were normal. An
electroencephalogram showed a generalized slowing
pattern consistent with metabolic encephalopathy.
Over the next 8 hours, the patient’s mental status
progressively deteriorated to a comatose state. The 5-
FU infusion pump was discontinued. Because the pa-
tient was no longer adequately protecting his airway,
the critical care team was consulted for patient intuba-
tion and admission to the intensive care unit. With an
apparent cause for the rapidly progressive cognitive
dysfunction still lacking, lactulose at a dose of 30 mL
every 4 hours was administered by nasogastric tube
shortly thereafter in an effort to correct the patient’s
encephalopathy. Phenytoin was continued.
Following the cessation of 5-FU and administra-
tion of lactulose, the patient gradually recovered over
the next 48 hours from his acute confusional state. He
experienced significant fatigue and muscle weakness,
but no further seizures. Successive ammonia levels
showed a decreasing trend. The patient was extubated,
and phenytoin was discontinued. This man was dis-
charged home on day 8 with instructions to follow up
with his medical oncologist the following week.
After discharge, the patient required several weeks
to recuperate before he could embark on additional
chemotherapy. Considering his presumed neuropsychi-
atric complication from FOLFOX chemotherapy,
raltitrexed (3 mg/m2) and oxaliplatin (130 mg/m2) were
given every 3 weeks as adjuvant treatment instead. This
therapy was provided on an inpatient basis because of
the insistence of the patient. No significant adverse
reactions were noted. Unfortunately, re-staging inves-
tigations shortly thereafter revealed three metastatic
lesions in the liver. We plan to continue with further
chemotherapy for this patient with the goal of potential
resection of his liver lesions in the future.
2. DISCUSSION AND CONCLUSIONS
Colorectal cancer (CRC) is a leading cause of cancer
morbidity and mortality in the developed world 1. In
Canada alone, approximately 20,000 new cases and
8500 deaths occur each year 2. The primary treatment
modality for localized CRC is surgical resection, but
more than 40% of stage II and III patients will still de-
velop disease recurrence within 5 years of initial diag-
nosis 3,4. Therefore, adjuvant systemic therapy is
offered to high-risk patients after surgery to eradicate
occult micrometastatic disease and to reduce the risk
of disease recurrence. Recent introductions of novel
cytotoxic (for example, oxaliplatin) and molecularly
targeted agents (for example, bevacizumab) into tra-
ditional 5-FU–based chemotherapy regimens have re-
sulted in improved disease-free and overall survival in
advanced disease, but at a cost of increased risk for
toxicities 5,6.
The fluorinated pyrimidine 5-FU is an anti-
metabolite and anti-neoplastic agent that has been used
to treat a variety of cancers, including those of colon,
rectum, breast, stomach, and pancreas. Although first
introduced in 1958, 5-FU continues to be the corner-
stone of current adjuvant chemotherapy protocols in
CRC, namely the Mayo and the FOLFOX regimens 7.
Common side effects of 5-FU are bone marrow sup-
pression leading to neutropenia and infections, and
gastrointestinal toxicities such as stomatitis, nausea,
vomiting, and diarrhea. Other less frequent adverse
effects include alopecia, photosensitivity, and rarely,
cardiotoxicity.
Albeit uncommon, 5-FU administration can also
cause both acute and delayed neurotoxicities. The acute
form typically presents as encephalopathy or a cer-
ebellar-type syndrome. The delayed variety usually
manifests as a subacute multifocal leucoencephalopa-
thy. Seizures such as those demonstrated by the pa-
tient in the current case are an unusual finding and have
only rarely been reported 8.
The precise mechanisms that underlie the various
neurotoxicities are poorly understood, although several
theories have been proposed. Some researchers believe
that a non-specific immune-mediated process is re-
sponsible, but others suggest a more simplistic model
in which ammonia, a product of 5-FU metabolism, ac-
cumulates in large amounts after either high-dose or
continuous 5-FU administration 9,10.
The diagnosis of 5-FU–related encephalopathy is
really one of exclusion. An astute clinical suspicion
for this condition among cancer patients is therefore
essential if early detection and prompt treatment are
to occur. Although the finding of an increased ammo-
nia level following chemotherapy administration sup-
ports the diagnosis, other metabolic and structural
causes of altered mental status such as hypoglycemia,
electrolyte disturbances, renal or hepatic failure, sep-
sis, medication intoxication or withdrawal, and brain
metastases must first be excluded, as occurred in this
case. Although our patient’s creatinine and blood urea
nitrogen were both elevated, neither reached a level at
which uremic encephalopathy would be anticipated.
In addition, the patient’s leucocytosis was the probable
result of his seizure activity, given that his infectious
disease workup was entirely negative.
Discontinuation of 5-FU is a mainstay in the initial
treatment of 5-FU encephalopathy. However, the opti-
mal “antidote” and appropriate steps in the subsequent
management of this condition remain unclear. Proposed
treatment modalities have varied considerably in the
literature, ranging from purely supportive measures to
the use of corticosteroids or thiamine (or both), which,
alone or in combination, have shown no consistent ef-
ficacy 8,11. In our case, the elevated ammonia level
prompted a trial of lactulose administered in a manner
similar to that used in hepatic encephalopathy. This
maneuver, in combination with 5-FU cessation, resulted
in timely symptomatic improvement in our patient.5-FU–INDUCED ENCEPHALOPATHY
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The present case is also unique in uncovering the
first patient to develop 5-FU encephalopathy as a result
of FOLFOX chemotherapy, which, over the past few
years, has quickly become the new standard of care in
the adjuvant and palliative therapies for CRC. Because
of current advances in screening and diagnostic strate-
gies, a growing number of CRC patients will be diagnosed
at a stage of disease that necessitates chemotherapy.
Although the rate of 5-FU neurotoxicity is low (<1%),
the increasingly prevalent use of FOLFOX chemotherapy
may influence the absolute incidence of this compli-
cation 12. Further research is needed to better deline-
ate and understand the mechanisms that contribute to
5-FU encephalopathy, but a high index of suspicion for
this entity is warranted until more definitive diagnostic
and therapeutic approaches are available. In the mean-
time, supportive care and empiric use of lactulose should
be considered during management.
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